<DOC>
	<DOCNO>NCT00049452</DOCNO>
	<brief_summary>RATIONALE : It yet know whether zoledronate effective prevent bone loss premenopausal woman receive adjuvant chemotherapy undergo surgery early stage breast cancer . PURPOSE : Randomized phase III trial determine effectiveness zoledronate prevent bone loss premenopausal woman receive chemotherapy surgery early stage breast cancer .</brief_summary>
	<brief_title>Zoledronate Preventing Bone Loss Premenopausal Women Receiving Chemotherapy After Surgery For Early Stage Breast Cancer</brief_title>
	<detailed_description>OBJECTIVES : - Compare change bone mineral density ( BMD ) bone turnover occur premenopausal woman resect early stage breast cancer 6 month adjuvant chemotherapy . - Determine factor predict bone loss chemotherapy , particularly induction amenorrhea , type chemotherapeutic regimen , glucocorticoid exposure , baseline BMD , patient . - Determine whether zoledronate prevents bone loss patient give adjuvant chemotherapy . - Determine effect zoledronate marker bone turnover patient adjuvant chemotherapy . - Determine whether effect marker bone turnover predicts response zoledronate patient . OUTLINE : This randomize , double-blind , placebo-controlled , multicenter study . Patients stratify accord estrogen receptor status ( positive v negative ) , progesterone receptor status ( positive v negative ) , adjuvant chemotherapy regimen . Patients randomize 1 2 treatment arm . - Arm I : Patients receive zoledronate IV 15 minute day 1 . - Arm II : Patients receive placebo IV 15 minute day 1 . In arm , treatment repeat every 3 month 4 course absence disease progression . Patients also receive calcium cholecalciferol ( vitamin D ) supplement daily . Quality life assess baseline 6 12 month . Patients follow 1 year . PROJECTED ACCRUAL : A total 120 patient ( 60 per treatment arm ) accrue study .</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Osteoporosis</mesh_term>
	<mesh_term>Zoledronic acid</mesh_term>
	<mesh_term>Diphosphonates</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Diagnosis localize breast cancer Stage I II ( T13 , N02 , M0 ) Planned adjuvant chemotherapy ( surgery ) least 6 month duration Hormone receptor status : Estrogen receptor progesterone receptor status know PATIENT CHARACTERISTICS : Age 18 50 Sex Female Menopausal status Premenopausal perimenopausal Performance status Not specify Life expectancy Not specify Hematopoietic Not specify Hepatic Not specify Renal Creatinine le 2 mg/dL Other No T score less 2.0 bone mineral density ( BMD ) No fragility fracture No lumbar spine anatomy would preclude accurate BMD measurement minimum 3 lumbar vertebra Not pregnant PRIOR CONCURRENT THERAPY : Biologic therapy Not specify Chemotherapy See Disease Characteristics Endocrine therapy Not specify Radiotherapy No concurrent radiotherapy Surgery See Disease Characteristics Other At least 1 month since prior calcitonin At least 12 month since prior bisphosphonates give 1 month duration No concurrent fluoride therapy ( 10 mg/day ) No concurrent enrollment another experimental drug study</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>April 2007</verification_date>
	<keyword>osteoporosis</keyword>
	<keyword>stage I breast cancer</keyword>
	<keyword>stage II breast cancer</keyword>
</DOC>